{
    "nct_id": "NCT06101823",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis",
    "inclusion_criteria": "* Subject has clinically confirmed diagnosis of active AD\n* Subject has at least a 6-month history of AD\n* Subject is willing to use effective birth control\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.\n* Subject has any clinically significant medical condition that would put the subject at undue risk or interfere with interpretation of study results.\n* Subject has used dupilumab within 26 weeks prior to Day 1\n* Subject has used tralokinumab within 12 weeks prior to Day 1",
    "miscellaneous_criteria": ""
}